Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02528409 · ClinicalTrials.gov registry record · Phase 2
Vortioxetine for Binge Eating Disorder
A Phase 2 study of Binge-Eating Disorder, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02528409: Completed Phase 2 study of Binge-Eating Disorder, sponsored by University of Chicago.
NCT02528409 is a Phase 2 study of Binge-Eating Disorder that has completed, run by University of Chicago. The registered enrollment target is 80 participants, below the 1,141-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02528409, a Phase 2 study of Binge-Eating Disorder, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.
Primary Outcome
Subjects will report the number of binge eating episodes in the week preceding the final visit (Week 12 of treatment), both to the investigator and via daily eating journals at all 9 visits. The outcome measure was the change in number of episodes from Week 0 (baseline) to the final visit (Week 12).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vortioxetine
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
What the finished NCT02528409 record still lists
NCT02528409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,141-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02528409 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02528409 about?
NCT02528409 is a clinical study titled "Vortioxetine for Binge Eating Disorder". The aim of the present study is to examine the efficacy and safety of vortioxetine vs placebo in adults with moderate to severe Binge eating disorder, as indicated by at least 3 binge eating days per week for the 2 weeks before the baseline visit.
What is the current status of trial NCT02528409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-06. Estimated completion is 2018-11-01.
What conditions does trial NCT02528409 study?
This clinical trial studies the following conditions: Binge-Eating Disorder.
What interventions are being tested in trial NCT02528409?
The interventions under investigation include: Placebo (DRUG), Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02528409?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02528409 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02528409's enrollment target sits among peer trials
80 18th of 37 higher than 20 of 37 other Binge-Eating Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Binge-Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
RECRUITING · Phase 2
-
A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
RECRUITING · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
COMPLETED · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
COMPLETED · Phase 2
-
Dasotraline Binge Eating Disorder Study
COMPLETED · Phase 2
-
Craving, Binge Eating and Obesity
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia